GlassScriptPhysician profile
Wesley W Goodrich
NPI 1194304600
$1,137.53
in general payments reported to CMS, 2019-2025
16 companies · $884 in 2025
The $884 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.83 · 2024: $231 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.46 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $156.79 | 2024-2025 | |
| Novo Nordisk INC | $127.01 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $90.45 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $64.86 | 2024-2025 | Evenity, Prolia, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.99 | 2024 | Xifaxan |
| Medtronic, INC. | $27.41 | 2025 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $25.69 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $22.43 | 2025 | Cologuard Collection Kit |
| Organon LLC | $21.83 | 2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $21.21 | 2025 | Rexulti |
| Acera Surgical, INC. | $20.00 | 2024 | Restrata Wound Matrix |
| Baxter Healthcare | $19.58 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $16.66 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $15.57 | 2025 | Contrave |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.59 | 2024 | Arexvy, Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Goodrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.